PCSK9 inhibitors are now one of the emerging non-statin lipid lowering agents which exhibited an increasing clinical benefits in patients and are used in different cardiovascular diseases (CVD) especially coronary heart diseases (CHD), myocardial infarction (MI), and stroke (Joseph and Robinson 2015; Tsivgoulis et al. 2018). This evidence concerns the gene PCSK9 and coronary artery disorder.